No Data
No Data
CalciMedica Is Maintained at Outperform by Oppenheimer
CalciMedica Is Maintained at Outperform by
Oppenheimer Maintains CalciMedica(CALC.US) With Buy Rating, Raises Target Price to $20
Oppenheimer analyst Leland Gershell maintains $CalciMedica(CALC.US)$ with a buy rating, and adjusts the target price from $14 to $20.According to TipRanks data, the analyst has a success rate of 34.2%
Express News | CalciMedica : Oppenheimer Raises Target Price to $20 From $14
Buy Rating Affirmed for CalciMedica's Auxora Amid Promising AKI Treatment Prospects
CalciMedica Begins Phase 2 Trial of Auxora for Acute Kidney Injury and Respiratory Failure
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition
Express News | CalciMedica Inc - Topline Data Expected in 2025
No Data